Enjoying the archive? Get new posts in your inbox.
GLP1
+2
Jun 16, 2026
•
9 min read
Glucagon Doesn't Win the Scale. It Wins the Liver.
Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.
CV
+1
Jun 13, 2026
•
7 min read
Zero Calcium. Doubled Plaque.
A new natural-history study watched atherosclerosis grow in untreated, low-risk adults over five years — and quietly made the strongest case I’ve seen in years for treating LDL early and aggressively.
CV
+2
Jun 9, 2026
•
10 min read
The Cholesterol You Were Born With
Lp(a) drives heart attacks, strokes, and aortic stenosis in one in five people. Statins don’t touch it. Diet doesn’t move it. After six decades of therapeutic silence, 2026 is the year the verdict finally arrives — and a single gene edit may make the problem history.
GLP1
+1
Jun 6, 2026
•
7 min read
GLP-1 Resistance Is Real. You Probably Don’t Have It.
A genetic study just caught true GLP-1 resistance in the act. Almost no one being called a “non-responder” fits the description.
GLP1
+1
May 23, 2026
•
9 min read
The Accidental Hormone.
A century-long hunt for a phantom gut hormone, a peptide chemist written out of the story, and a venomous desert lizard. Here is where Ozempic actually comes from — and who actually found it.
